Topic

Found 728,006 articles

• Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line

  5/8/2023

  Enzolytics, Inc. announced that the Company's wholly owned subsidiary, Virogenetics (VIRO), will be conducting a pilot clinical trial test for the state owned Bulgarian National Center for Endocrinology to gauge the effectiveness of the ITV-1 immunotherapy on Diabetes.

• Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

  5/8/2023

  Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced the launch of “Don’t Freak Out.

• Solarea Bio Announces First Close of Series B Financing Round

  5/8/2023

  Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.

• Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR

  5/8/2023

  Neuronetics, Inc., a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced its certification in two enhanced compliance programs.

• MBX Biosciences to Participate in May 2023 Investor Conferences

  5/8/2023

  MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ therapeutics to treat an array of endocrine disorders, announced management will participate in the following investor conferences.

• New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

  5/8/2023

  INOVIO presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

• eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference - May 08, 2023

  5/8/2023

  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the JMP Securities Life Sciences Conference taking place May 15-16, 2023 in New York, NY.

• Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors

  5/8/2023

  CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it has appointed Bettina M. Cockroft, M.D., M.B.A., to its Board of Directors as an independent director.

• Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference - May 08, 2023

  5/8/2023

  Cue Biopharma, Inc. announced that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.

• Siemens Healthineers Enters into Agreement with Scopio Labs to Distribute Full-Field Digital Cell Morphology Technology

  5/8/2023

  Siemens Healthineers announced its entrance into an agreement to distribute Scopio Labs' full-field digital cell morphology technology, which will enable clinical laboratorians to examine patient blood cell samples digitally instead of under a microscope.

• Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

  5/8/2023

  Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2023.

• Benitec Biopharma to Present at the OPMD International Conference

  5/8/2023

  Benitec Biopharma Inc. announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present virtually on the BB-301 Clinical Development Program at the Oculopharyngeal Muscular Dystrophy International Conference in Tel Aviv, Israel, on Tuesday, May 16th, 2023 at 12:50 pm Israel Daylight Time.

• Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

  5/8/2023

  Lumos Pharma, Inc. announced that interim data from its OraGrowtH210 Trial were reviewed in an oral presentation at the 2023 Annual Meeting of the Pediatric Endocrine Society, held in San Diego, California, May 5-8, 2023.

• Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™

  5/8/2023

  Dyadic International, Inc. announced that it entered into a co-development and marketing agreement with Fermbox Bio Inc.

• Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

  5/8/2023

  Krystal Biotech, Inc. today reported financial results and key operational progress updates for the first quarter ended March 31, 2023.

• Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

  5/8/2023

  Rhythm Pharmaceuticals, Inc. announced that Health Canada has approved IMCIVREE® for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome or genetically-confirmed biallelic pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance.

• Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023

  5/8/2023

  Temple Therapeutics presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company’s platform that won the Eurostar Eureka peer-reviewed grant process in 2019 for ovarian cancer.

• Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept

  5/8/2023

  Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced it will host a virtual Key Opinion Leader event on its late-stage oncology asset, batiraxcept, on Wednesday, May 24, 2023 at 1:00pm ET.

• Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update

  5/8/2023

  Alimera Sciences, Inc. announces that it will report first quarter financial results on May 15, 2023, prior to the market open.

• SynCrest Launches CRDMO Service for Peptide-based Therapeutics

  5/8/2023

  SynCrest Inc., a peptide and nucleotide CRDMO joint venture between Otsuka Chemical Co., Ltd. and Yokogawa Electric Corporation, announces its services are now available for pharmaceutical companies and research institutions in Japan, Europe, North America, and South America.